Comparative Study on Efficacy of a Combination Therapy of Triamcinolone Acetonide Administration with and without Vitrectomy for Macular Edema Associated with Branch Retinal Vein Occlusion

2007 ◽  
Vol 39 (4) ◽  
pp. 207-212 ◽  
Author(s):  
Yoshio Hirano ◽  
Eiji Sakurai ◽  
Munenori Yoshida ◽  
Yuichiro Ogura
Keyword(s):  
Combination Therapy ◽  
Comparative Study ◽  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Vein Occlusion

EFFICACY OF COMBINED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE IN PATIENTS WITH NON-RESOLVING MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

2021 ◽  
pp. 48-49
Author(s):  
Haniyaa Mufti ◽  
Syed Tariq Qureshi ◽  
Birjees Hakak
Keyword(s):  
Combination Therapy ◽  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Common Adverse Effect ◽  
Visual Outcome ◽  
Intravitreal Injections ◽  
Therapeutic Effects ◽  
Vein Occlusion

Purpose: To study the effects of combined intravitreal injections of bevacizumab (IVB) and triamcinolone acetonide (IVTA) in patients with non-resolving macular edema (ME) secondary to Branch Retinal Vein Occlusion (BRVO). Methods: In a prospective observational study, 50 pseudophakic eyes of BRVO patients with non-resolving central macular edema who had received more than 3 doses of IVB previously were injected with combination therapy of 1.25 mg/0.05 ml IVB and 4 mg of IVTA and followed up for 6 months with best corrected visual acuity(BCVA), intraocular pressure(IOP) and central macular thickness(CMT) Results: The mean BCVA was logMAR 0.75±0.25 at baseline and 0.65±0.15, 0.48±0.20, and 0.22±0.25 at 6weeks, 3 months and 6 months respectively. Mean CMT at baseline was 668.32±254.66 and 434.43±99.55, 243.22±58.92, and 220.83±42.60 at 6 weeks, 3 months and 6 months respectively. Baseline IOP measured was 16.5±3.1 mmHg which progressed to 19.6±3.4mmHg and 21.4±2.8mmHg at 6 weeks and 3 months respectively and decreased to 17.3±2.2 at 6 months. The most common adverse effect seen was increase in IOP in 24(48%)patients, out of which 3(6%) patients needed to start anti-glaucoma medication (AGM). 3(6%) patients had sub-conjunctival hemorrhage(SCH). Conclusion: The prolonged therapeutic effects of combination therapy leads to outstanding anatomical and visual outcome in non resolving ME due to BRVO, with fewer doses and thus fewer adverse effects.

Sign in / Sign up

Export Citation Format

Share Document